Dendritic cells play a key role in determining adaptive immunity, and there is growing interest in characterizing and manipulating the interactions between dendritic cells and biomaterial surfaces. Contact with several common biomaterials can induce the maturation of immature dendritic cells, but substrates that reduce dendritic cell maturation are of particular interest within the field of cell-based therapeutics where the goal is to reduce the immune response to cell-laden material carriers. In this study, we use a materials-based strategy to functionalize poly(ethylene glycol) hydrogels with immobilized immunosuppressive factors (TGF-b1 and IL-10) to reduce the maturation of immature dendritic cells. TGF-b1 and IL-10 are commonly employed as soluble factors to program dendritic cells in vitro, and we demonstrate that these proteins retain bioactivity towards dendritic cells when immobilized on hydrogel surfaces. Following stimulation with lipopolysaccharide (LPS) and/or cytokines, a dendritic cell line interacting with the surfaces of immunosuppressive hydrogels expressed reduced markers of maturation, including IL-12 and MHCII. The bioactivity of these immunomodulatory hydrogels was further confirmed with primary bone marrow-derived dendritic cells (BMDCs) isolated from non-obese diabetic (NOD) mice, as quantified by a decrease in activation markers and a significantly reduced capacity to activate T cells. Furthermore, by introducing a second signal to promote BMDC-material interactions combined with the presentation of tolerizing signals, the multifunctional PEG hydrogels were found to further increase signaling towards BMDCs, as evidenced by greater reductions in maturation markers.
Introduction
Dendritic cells (DCs) bridge the innate and adaptive immune systems and are crucial to initiating and guiding the adaptive immune response. Immature dendritic cells (iDCs) survey the body's periphery in search of foreign and self antigens [1] . Upon antigen uptake, DCs present antigen to lymphocytes, but have the unique capacity to induce either immunity or tolerance to antigen [1, 2] . For example, when iDCs encounter antigen in the presence of stimulatory factors such as "danger signals" or pathogen associated molecular patterns (PAMPs), iDCs undergo maturation into mature DCs and initiate an adaptive immune response [3] . Upon maturation, DCs increase expression of MHC stimulatory molecules, B7 family co-stimulatory molecules (i.e., CD80 and CD86), and inflammatory cytokines, including IL-12, which enable the activation of naïve CD4 þ helper T cells to initiate an immune response [1] .
Conversely, if iDCs encounter antigen under conditions which prevent full DC maturation, they express an altered pattern of surface proteins, preventing an unfavorable adaptive immune response [2, 4] . Because of their critical importance in dictating the fate of the adaptive immune response, understanding interactions between iDCs and implanted biomaterial surfaces has gained considerable interest in recent years [5] . For example, several commonly-used biomaterials including poly(lactic-co-glycolic acid) (PLGA) and chitosan [6] , as well as surface modifications with common extracellular q Editor's Note: This paper is one of a newly instituted series of scientific articles that provide evidence-based scientific opinions on topical and important issues in biomaterials science. They have some features of an invited editorial but are based on scientific facts, and some features of a review paper, without attempting to be comprehensive. These papers have been commissioned by the Editor-in-Chief and reviewed for factual, scientific content by referees.matrix (ECM) proteins [7] and integrins [8] , have been identified as regulators that can induce iDC maturation and initiate an adaptive immune response. The induced maturation of iDCs by biomaterials, or adjuvant effect, is desirable for vaccines against infection and tumors where an immune response is favorable [9] . However, in the design of biomaterials for cell delivery, such as the encapsulation of tissues for transplantation, ideal biomaterial cell carriers would prevent the full maturation of iDCs. Babensee and coworkers recently demonstrated that hyaluronic acid and agarose have the capacity to limit immunogenicity compared to surfaces with known adjuvant effect [6, 10] , but in general, the investigation of strategies to actively limit iDC maturation via controlled modification of biomaterial surfaces has been limited. In solution, however, iDCs have been cultured in the presence of one or more soluble factors such as transforming growth factor b-1 (TGF-b1) and/or interleukin 10 (IL-10) [11e14]. Resulting DCs have been reported to undergo incomplete maturation upon immune stimulation and can promote T cell anergy or induce regulatory T cell production [2] . For example, Torres-Aguilar et al. recently cultured iDCs with IL-10 and TGF-b1 in the presence of insulin to generate DCs that could induce antigen-specific insulin tolerance in humans [15] .
Numerous proteins, peptides and other molecules of interest have been previously incorporated onto biomaterial surfaces and remained bioactive for cell signaling [16, 17] . We have previously investigated PEG-based surfaces for the purposes of immune signaling, and demonstrated that PEG coatings containing immobilized anti-fas are capable of interacting with T cells and inducing apoptosis [18e20]. Notably, Mann et al. tethered TGF-b1 within PEG hydrogels to signal vascular smooth muscle cells and demonstrated that immobilized TGF-b1 maintained bioactivity and increased ECM protein synthesis [21] . Further, it is known that DCs have the capacity to receive biological cues from tethered signaling proteins, as Leclerc et al. immobilized granulocytemacrophage colony stimulating factor (GM-CSF) upon surfaces to promote the development of iDCs from isolated bone marrow tissue [22] . In the study we describe herein, a general approach to modify biomaterial surfaces with thiolated proteins, specificallyTGF-b1 and/or IL-10, to create immunomodulatory surfaces that signal iDCs and reduce maturation upon stimulation with LPS. A poly(ethylene glycol) (PEG) hydrogel platform, which limits immunogenicity and allows facile modification for incorporation of proteins, was chosen as a basis for tethering anti-inflammatory molecules for iDC signaling. By introducing a second signal that promoted cellematerial interactions, along with the immunomodulatory signals, multifunctional PEG hydrogel surfaces could be tailored to suppress iDC maturation to a greater degree than either signal alone.
Materials and methods

Dendritic cell culture
Initial studies were conducted with the cytokine-dependent, immortalized immature dendritic cell line, JAWSII. The JAWSII dendritic cell line was originally isolated from the bone marrow of p53 À/À C57BL/6 mice and has been previously shown to mimic the capacity of primary iDCs to undergo maturation in response to immune stimuli [23e26] . JAWSII cells, an immortalized dendritic cell line of murine bone marrow origin (ATCC, Manassas, VA), were cultured in a-MEM media (Invitrogen, Carlsbad, CA) supplemented with 20% heat inactivated FBS (Invitrogen), 1% penicillin/streptomycin (Invitrogen), and 5 ng/ml GM-CSF (Peprotech, Rocky Hill, NJ). JAWSII were cultured in tissue culture flasks and media was changed weekly. Additionally, primary bone marrow-derived DCs (BMDCs) generated from bone marrow isolated from non-obese diabetic (NOD) mice were evaluated with immunomodulatory hydrogels. Primary BMDCs were harvested from femurs isolated from NOD mice (4e10 weeks old). The ends of femurs were cut and the marrow was rinsed with 10 ml RPMI media 1640 (Invitrogen) with a 27 gauge syringe needle.
Freshly isolated samples were then mixed in an 18 gauge syringe to dissociate clumps and the resulting cell suspension was cultured in media consisting of RPMI 1640 supplemented with 1.5% mouse serum (Invitrogen), 20 ng/ml GM-CSF, and 1% penicillin/streptomycin. BMDCs were seeded onto tissue culture polystyrene (TCPS) in 6-well plates or hydrogels in 96-well plates and 50% fresh media volume was changed daily.
Thiolation of proteins
To incorporate TGF-b1 and IL-10 as covalent pendant functional groups within hydrogels, proteins were rendered polymerizable via modification by Traut's reagent (Thermo Scientific, Rockford, IL), which conjugates to free amines to create thiols. In brief, proteins were reconstituted in phosphate buffered saline (PBS, pH 7.4, Invitrogen) containing 2 mM EDTA (Sigma) and a 5-fold molar excess Traut's reagent per mol protein. Samples were mixed and reacted at room temperature for 1 h. Following thiolation, unreacted Traut's reagent was removed via filtration through ZebaÔ Spin Desalting Columns (7 K MWCO, Thermo Scientific), yielding the final thiolated product of TGF-b1-SH or IL-10-SH. Samples were diluted to a final concentration of 25 mg/ml in PBS with 2 mM EDTA and immediately placed in a À80 C freezer. Prior to use, protein solutions were rapidly thawed and added to pre-polymer solutions in concentrations ranging from 0 to 1 mg/ml for gel formation via photopolymerization.
PEG hydrogel formation
The synthesis of poly(ethylene glycol) (PEG) diacrylate (PEGDA, 10 kDa) macromolecular monomers from hydroxyl-PEG (Sigma) has been described in detail elsewhere [27] . Briefly, hydroxyl PEG was dissolved in anhydrous toluene by heating to 60 C with mixing. After the dissolved PEG was allowed to cool to room temperature (RT), triethylamine (TEA, 4-fold molar excess per hydroxyl group) and acryloyl chloride were added and reacted overnight at RT with stirring. Next, TEA was removed via filtration through neutral alumina. PEGDA was precipitated in cold diethyl ether and desiccated to dryness overnight. To ensure high levels of purity, PEGDA was dialyzed against deionized water overnight (1 kDa MWCO membrane) with >3 dialysis volume changes.
Pre-polymer solutions were prepared consisting of 10 wt% PEGDA in PBS with 0.05 wt% of the photoinitiator 2-hydroxy-4 0 -(2-hydroxyethoxy)-2-methylpropiophenone (Irgacure-959, Ciba Specialty Chemicals) and thiolated proteins (0e1 mg/ml). For selected studies, poly-L-lysine (PLL, 10 mM, Sigma), laminin (200 mg/ml, BD Biosciences, Bedford, MA) or fibronectin (200 mg/ml, BD Biosciences)
were also included in pre-polymer solutions. Pre-polymer solutions were loaded into the tips of 1 ml syringes (30 ml) and polymerized for 10 min under ultraviolet light (6 mW/cm 2 , centered at 365 nm) for gel formation. Following polymerization, hydrogels were incubated overnight in either PBS or cell culture media (4 C, with orbital shaking) with at least two solution changes to ensure complete removal of residual photoinitiator and untethered proteins. The final, swollen hydrogels were disks with a diameter of w5.5 mm and height of w2 mm.
Measurement of incorporated proteins
TGF-b1 was added to pre-polymer solutions in concentrations ranging from 0 to 1 mg/ml. Following photopolymerization, functionalized hydrogels were rinsed overnight in 3 ml PBS with >2 solution changes to ensure complete removal of noncovalently bound protein.
The following day, a modified ELISA was employed to quantify the concentration of protein on the gel surface. Hydrogels were incubated with anti-TGF-b1 monoclonal antibody from mouse (5 mg/ml, Peprotech) in ELISA buffer (sterile filtered PBS with 0.1% BSA and 0.05% TWEEN-20) for 1.5 h and then rinsed three times with ELISA buffer. Next, samples were incubated with horseradish peroxidase-conjugated goat anti-mouse secondary antibody (100 ng/ml, Jackson ImmunoResearch, West Grove, PA) for 30 min, followed by three rinses with PBS. Samples were then incubated for 60 min in ELISA buffer, rinsed three times, and incubated another 15 min in ELISA buffer to ensure complete removal of unbound antibodies. Hydrogels were distributed into individual wells of a 96-well plate containing 70 ml PBS (30 ml hydrogel plus 70 ml PBS resulted in roughly 100 ml total volume/well), and the TMB ELISA substrate (100 ml/well, Thermo Scientific) was added for 20 min. Finally, the reaction was quenched via the addition of 100 ml H 2 SO 4 100 ml combined TMB/H 2 SO 4 and the absorbance was measured at 450 nm and compared to that of standards prepared from known quantities of secondary antibody, TMB, and H 2 SO 4 .
PE-25 TGF-b reporter cell assay
The presence of biologically active TGF-b1 on hydrogel surfaces was verified using a PE-25 TGF-b reporter cell line (i.e., mink lung epithelial cells (Mv1Lu or CCL-64)) containing a stably transfected luciferase reporter gene for TGF-b which were generously donated by Dr. Xuedong Liu [28] . PE-25 cells were seeded atop functionalized hydrogels at a density of 1 Â 10 5 cells/ml for 24 h in 200 ml Dulbecco's Modified Eagle Medium (Invitrogen). The following day, the media was gently removed and samples were lysed via the addition of 200 ml passive lysis buffer (Promega, Madison, WI) and incubated for 10 min at 37 C, with shaking, and finally stored at À80 C for >2 h. Next, the samples were thawed, transferred to microcentrifuge tubes and centrifuged for 10 min (13,000 rpm, 4 C). The lysate was transferred to white, opaque-walled 96-well plate (100 ml per well), and 50 ml luciferase substrate (Promega) was added to each well for 5 min and then luminescence was quantified.
JAWSII DC studies
JAWSII DCs were seeded into 96-well plates on either empty wells (TCPS) or atop hydrogels at a density of 3.0 Â 10 5 cell/ml in 200 ml JAWSII cell culture media. Cells were cultured atop blank and functionalized (TGF-b1-SH and/or IL-10-SH) hydrogels or on TCPS with or without the addition of soluble TGF-b1 and/or IL-10-SH for three days. On day 4, DCs were activated via the addition of lipopolysaccharide (LPS, 1 mg/ ml, Sigma), with interferon gamma (IFN-g, 10 ng/ml), tumor necrosis factor alpha (TNF-a,10 ng/ml) and interleukin 4 (IL-4,10 ng/ml), each obtained from Peprotech. On day 6, 100 ml of each sample was analyzed for IL-12p70 production via an ELISA kit (eBioscience, San Diego, CA) per the manufacturer's instructions. For flow cytometry analysis, JAWSII were removed from TCPS and hydrogels via incubation in cold PBS (10 min on ice). For flow cytometry analysis, samples were rinsed in PBS þ 10% FBS and then incubated for 10 min at 4 C with Fc Block (anti-mouse CD16/CD32, Fcg III/II Receptor, BD Pharmingen, San Diego, CA). FitC-rat anti-mouse I-A/I-E (clone 2G9, BD Pharmingen) and PE-rat anti-mouse CD86 (clone GL1, BD Pharmingen); antibodies were added and allowed to stain for 60 min at 4 C. Fluorescently labeled antibody isotypes were included as controls. Following staining, samples were rinsed and then analyzed using a CyAn Flow Cytometer and Summit software (Beckman Coulter) and more than 25,000 events were collected per sample.
BMDC studies
BMDCs were harvested from NOD mice and then seeded in 6 well plates at 5 Â 10 6 cells/well, in 4 ml BMDC media for four days. Half of the BMDC media was exchanged b-SH and/or IL-10. Half of the media volume was exchanged with fresh media each day. On day 8, samples were activated via the addition of LPS (1 mg/ml). On day 8, 100 ml of supernatant per sample was harvested and the IL-12p70 concentration was quantified via ELISA. Cells were lifted for flow cytometry by incubation in PBS with 5 mM Na 2 EDTA (Sigma) for 20 min at 37 C. Cells were rinsed with 1% BSA in PBS and stained with Fc block (anti-mouse CD16/CD32, Fcg III/II Receptor, BD Pharmingen) for 10 min on ice. Next, samples were stained with one or more of the following: FitCanti-MHCII (Clone: RI1B, Ox-6, BD Pharmingen), FITC-anti-CD86 (Clone: GL1, BD Pharmingen), PerCP-anti-CD11b (Clone: M1/70, BD Pharmingen), PE-anti-CD80 (Clone: 16-10A1, BD Pharmingen), APC-Anti-CD11c (Clone: N418, BD Pharmingen), Cells were incubated for 30 min on ice, were rinsed 3 times, and re-suspended for flow cytometry. Samples were analyzed by FACS Caliber.
T cell activation studies
The diabetogenic CD4 Th1 T cell clone BDC-2.5 was derived from spleen and lymph node cells of a diabetic NOD mouse [29, 30] . T cells were maintained by restimulation with an antigenic membrane fraction from b-cell tumors [31] , irradiated NOD spleen cells as antigen-presenting cells (APC), and IL 2 in complete medium (CM). CM is Dulbecco's modified Eagle's minimal essential medium (DMEM) (Life Technologies, Gaithersburg, MD) supplemented with 44 mM sodium bicarbonate, 0.55 mM L-arginine, 0.27 mM L-asparagine, 1.5 mM L-glutamine, 1 mM sodium pyruvate, 50 mM 2-ME, 10 mM HEPES, and 10% fetal bovine serum. At the end of the two-week cycle, T cells (2 Â 10 4 ) were cultured with beta cell antigen and BMDCs (1.88 Â 10 5 cells/ml) as APCs in 96-well plates to assay for T cell responses. Supernatants were harvested 72 h later and IFN-g production was measured by ELISA. 
Statistical analysis
Statistical significance was determined using a two-tailed, unpaired Student's ttest. Differences between datasets were considered statistically significant when the p value was less than 0.05. All results are presented as mean AE standard error of the mean. Each experiment was repeated at least twice.
Results
Bioactivity of thiolated TGF-b1
TGF-b1 was converted into a polymerizable form via thiolation with Traut's reagent [32] , as schematically illustrated in Fig. 1A . To confirm that TGF-b1-SH remained bioactive, PE-25 (TGF-b reporter) cells were incubated overnight with 0, 1.0 and 10 ng/ml of soluble and unmodified TGF-b1 as compared to TGF-b1-SH. The following day, luciferase activity was quantified as a marker of TGF-b bioactivity. As shown in Fig. 1B , at a concentration of 1.0 ng/ml, a reduction in TGF-b1-SH bioactivity was observed compared to unmodified TGF-b1. At 10 ng/ml, however, both thiolated and unmodified TGF-b1 resulted in high levels of luciferase activity. Bioactivity was also verified via activity with JAWSII DCs. Dendritic cells were incubated with thiolated and unmodified TGF-b1 for 24 h (10 ng/ml) and then activated via stimulation with LPS and IFN-g. As presented in Fig. 1C , both forms of TGF-b1 were able to suppress DC IL-12 production when challenged with LPS, indicating that the bioactivity of TGF-b1-SH was preserved. The same effect was observed with soluble IL-10-SH, shown in Fig. 1D .
The surface expression of MHCII (Fig. 1E) and CD86 (Fig. 1F) was also characterized for JAWSII iDCs cultured with both soluble TGFb1-SH and/or IL-10-SH. As anticipated, stimulation resulted in a large increase in MHCII expression. However, pre-treatment with either TGF-b or IL-10 resulted in DCs with decreased MHCII expression, compared to stimulated controls. Although stimulation also increased the levels of CD86, pre-treatment with immunosuppresants did not affect CD86 expression by JAWSII DCs.
Formation of immunomodulatory PEG hydrogels
To create functional material systems, PEGDA (10 kDa, 10 wt%) hydrogels were photopolymerized with or without the addition of thiolated proteins, Fig. 2A . Free thiols on proteins were covalently incorporated within hydrogel networks via a mixed-mode, radicalmediated, thiol-acrylate polymerization, as previously described [33] . A modified ELISA was employed to characterize the concentration of TGF-b1 available on the hydrogel surface. As illustrated in Fig. 2B , an increase in the detectable surface concentration of TGFb1 was observed relative to the concentration of TGF-b1-SH included in the pre-polymer solution. When TGF-b1-SH (1.0 mg/ ml) was included in the pre-polymer solution, TGF-b1 (18 AE 2 pg/ cm 2 ) was detected on the gel surface. To verify the bioactivity of the TGF-b1 hydrogels, PE-25 TGF-b reporter cells were seeded on gels and allowed to interact for 24 h. Luciferase activity was quantified, and as shown in Fig. 2C , significant TGF-b bioactivity was measured on the hydrogel surfaces fabricated with the TGF-b-SH. 
JAWSII DCs on immunomodulatory hydrogels
JAWSII iDCs were seeded on hydrogels functionalized with or without the immunosuppressive proteins, TGF-b1 and/or IL-10, and cultured for 3 days. As shown in Fig. 3A , JAWSII iDCs were seeded on hydrogels substrates fabricated with 0, 0.1, and 1.0 mg/ml TGFb1-SH in the pre-polymer solution. Following stimulation, JAWSII cultured on hydrogels with TGF-b1-SH secreted lower amounts of IL-12, compared to stimulated controls. A marked reduction in IL-12 in response to stimulation was also observed for DCs seeded on hydrogel surfaces containing IL-10, as well as for surfaces duallyfunctionalized with TGF-b1 and IL-10, as shown in Fig. 3B . Stimulated JAWSII DCs on dually-functionalized gels secreted 63% less IL-12 than DCs cultured on unmodified control hydrogels, providing evidence that the immobilized immunosuppressant biological signals remained active and signaled the DCs.
Flow cytometric analysis was performed on JAWSII DCs harvested after seeding on functionalized hydrogels. Increased surface expression of the MHCII and CD86 is commonly observed with these markers of DC maturation, and their expression on JAWSII DCs has been previously observed to correlate with activation state [24] . As illustrated in Fig. 3 , JAWSII DCs upregulated MHCII (Fig. 3C ) and CD86 (Fig. 3D ) expression in response to stimulation. Seeding JAWSII on TGF-b1, IL-10, or dually-functionalized gels, however, significantly decreased the percentage of MHCII þ DCs following stimulation (Fig. 3C) . As observed when JAWSII were incubated with soluble immunosuppressants (Fig. 1F ), CD86 expression was not affected by hydrogel functionalization (Fig. 3D) . In sum, culturing JAWSII with either soluble or immobilized immunosuppressants generated DCs with similar IL-12, MHCII, and CD86 expression, demonstrating the bioactivity of immunomodulatory hydrogels.
Treating BMDCs with soluble TGF-b1 and IL-10
As further evidence of localized immune modulation of DC markers by soluble TGF-b1 and IL-10, we examined primary cells, bone marrow-derived dendritic cells (BMDCs) harvested from NOD mice. BMDCs were first treated with soluble TGF-b1-SH and IL-10-SH; selected samples were stimulated with LPS to induce BMDC maturation, and the media supernatant was assayed for IL-12. Surface levels of MHCII, CD80 and CD86 were assayed via flow cytometry. All samples were co-stained for the dendritic cell marker CD11c, and most of the CD11c þ cells were also CD11b þ .
Levels of MHCII (Fig. 4A) , CD80 (Fig. 4B ) and CD86 (Fig. 4C) were reduced in CD11c þ DCs cells by treatment with soluble immunomodulatory factors. Following stimulation with LPS, DCs expressed stimulatory and co-stimulatory markers. The expression of these markers was reduced, however, by pre-treatment with soluble immunosuppressive factors prior to LPS exposure. As shown in Fig. 4D , control BMDC cultures treated with LPS secreted markedly higher levels of IL-12. When pre-treated with soluble TGF-b1-SH and IL-10-SH, however, levels of IL-12 were significantly lowered, indicating a less mature phenotype.
Culturing BMDCs with immunomodulatory PEG hydrogels
BMDCs were cultured on the surfaces of functionalized and unmodified gels and then stimulated with LPS. IL-12 production was quantified, as shown in Fig. 5A , and, again a significant increase in cytokine production was observed for LPS-stimulated samples. The presence of immunomodulatory factors on the surfaces of the otherwise blank hydrogels, however, only slightly reduced iDC maturation, as evident by a small but significant decrease in IL-12 production with TGF-b1 and IL-10 on the hydrogel surface. We hypothesized that this effect might be due to limited interaction between the immature BMDCs and the PEG surface, as PEG is well documented to resist cell and protein adhesion.
To increase interaction between BMDCs and PEG surfaces, two strategies were explored to promote adhesion. Either poly-L-lysine (PLL) or the extracellular matrix (ECM) proteins, fibronectin and laminin, were incorporated into PEG hydrogels to promote cellular interactions. It is previously known that PLL is cytotoxic at high concentrations, however, when concentrations 10 nM were incorporated with PEG hydrogels, no reduction in cellular metabolic activity was observed after 48 h of dendritic cell culture atop gels, as shown in Fig. S1 . Therefore, 10 nM PLL was utilized for subsequent studies. Fibronectin & laminin did not adversely affect cells survival (data not shown). Visually, hydrogel surfaces containing either PLL or ECM proteins appeared to promote iDC/surface interaction, as depicted in Fig. S2 . On unmodified PEG hydrogels, BMDCs had a tendency to aggregate, while PLL and ECM hydrogels promoted single-cell attachment to the surface. BMDCs were cultured on PLL and ECM hydrogels functionalized with TGF-b1 and IL-10, and then stimulated with LPS. When seeded on hydrogels cofunctionalized with PLL or ECM and immunosuppressive factors, IL-12 measured post-stimulation was decreased by more than 50%, Fig. 5B and C. Furthermore, the surface maturation markers, MHCII, CD80 and CD86, were generally reduced prior to and following immune stimulation on immunomodulatory hydrogels, as shown in Fig. 6 . The decrease in IL-12 and surface marker expression in these experiments demonstrate that the immunosuppressive hydrogels can result in reduced maturation of BMDC.
Co-culture of BMDCs with T cells
To assess the functional capacity of BMDCs to activate T cells, BMDCs and T cells were co-cultured. As illustrated in Fig. 7A , unstimulated dendritic cells lacked the capacity to activate T cells, evidenced by negligible IFN-g production. Upon LPS stimulation, however, the BMDCs underwent maturation and were able to activate T cells, as indicated by increased T cell IFN-g secretion.
When BMDCs were pre-treated with soluble TGF-b and IL-10 prior to stimulation, T cell IFN-g production was significantly decreased, indicating reduced T cell activation by dendritic cells (Fig. 7A) . Further, these effects were confirmed when dendritic cells were cultured on hydrogels functionalized with tethered immunosuppressive molecules and PLL (Fig. 7B) , providing biological confirmation of the immunosuppressive activity of these functionalized hydrogels on DCs.
Discussion
Thiolation of TGF-b1 and IL-10 was achieved via reaction with Traut's reagent [32] , which preserved the bioactivity of target proteins and allowed protein to be successfully conjugated to hydrogel networks. Thiolated proteins were added to the prepolymer mixture and reacted into PEG hydrogels, utilizing a thiol-acrylate mixed-mode photoinitated polymerization. As a consequence, proteins were likely present throughout the hydrogel network as well as on the gel surface. The presence of protein accessible on the hydrogel surface was verified by a modified ELISA, whereby functionalized gels were incubated with a detection antibody. As has been previously reported, antibodies (w150 kDa MW) do not diffuse readily within PEGDA hydrogels on short time scales [34] , so protein was detectable only if immobilized and available for binding on the hydrogel surface. Significant surface protein was detectable, quantifiable, and found to be dependent upon the protein concentration added to the prepolymer solution.
JAWSII DCs were seeded on the surfaces of hydrogels functionalized with TGF-b1 and/or IL-10 to assess bioactivity towards DCs. When cultured on the gels, IL-12 production was suppressed upon stimulation, as was MHCII expression. These molecules were both suppressed to a similar extent by either soluble or immobilized factors, indicating decreased DC maturation and providing evidence that immobilized immunosuppressive factors retain bioactivity for DCs. While the suppression of IL-12 production and MHCII expression was successfully provided by TGF-b1 and/or IL-10, the CD86 co-stimulatory molecule was unaffected. This finding is in contrast to previous observations of decreased costimulatory marker expression on stimulated DCs that have been pre-treated with TGF-b1 and IL-10 [2] . Because this finding was consistent for pre-treatment with either soluble or immobilized factors, it is likely that the reduced sensitivity of co-stimulatory expression to immunosuppressive signaling is an inherit property of the JAWSII cell line and not a result of signaling molecule immobilization.
The bioactivity of immunomodulatory hydrogels was further assessed through experiments with primary BMDCs isolated from NOD mice. NOD mice were chosen as the BMDC source in these studies because this animal line is prone to autoimmunity and is a model for Type I diabetes. Type I diabetes has the potential to be cured via cell transplantation, so reducing the immune response to promote graft acceptance has been widely studied within Type I diabetes models. Therefore, we sought to demonstrate the capacity for immunosuppressive hydrogels to reduce NOD mouse dendritic cell activation because this has applications towards graft cytoprotection in a relevant disease model. The activation marker expression profile for BMDCs from NOD mice before and after immune stimulation has been previously characterized [35, 36] , and the activation controls reported herein were in good agreement with previous findings [37] . When the BMDCs were treated with soluble, thiolated immunosuppressive proteins, reductions in stimulatory (MHCII), co-stimulatory (CD80 & CD86) and cytokine (IL-12) molecules were observed, in good agreement with previous results [2] . Primary BMDCs were seeded on functionalized hydrogels in order to assess the capacity of the immobilized proteins to signal DCs. Initially, it was observed that PEG hydrogels modified with immunosuppressive factors alone delivered limited signaling to seeded BMDCs, as equivalent IL-12 was produced with our without immunosuppressive factors following stimulation with LPS. We hypothesized that this effect might be due to limited interaction between cells and the PEG surface, as PEG hydrogels have been previously shown to resist cell adhesion. Others have observed that the addition of adhesion ligands to biomaterial surfaces promotes cell attachment and increased cell signaling [38] , and we recently reported that the addition of ICAM-1 to PEG surfaces promoted T cell signaling [19] . Therefore, we investigated two methods of introducing adhesion molecules within the PEG hydrogels, either the addition of PLL or the incorporation of the ECM proteins, fibronectin and laminin.
Laminin and fibronectin were incorporated into PEG hydrogels to promote DC adhesion. When seeded upon ECM hydrogels, BMDCs secreted modestly elevated IL-12 in the absence of LPS stimulation, compared to cells seeded on blank hydrogels. The inherent ability of ECM-functionalized materials to induce the maturation of iDCs has been previously reported [7, 37] , so it is not surprising we observed this effect. It was encouraging to note, however, that the introduction of TGF-b1 and IL-10 to the ECMtethered surfaces significantly reduced the production of IL-12 and expression of MHCII, CD80 and CD86 by BMDCs. The observations that immobilized immunosuppressive proteins have the capacity to suppress ECM-mediated iDC maturation, as well as prevent maturation upon LPS stimulation, provide a striking illustration of the bioactivity of immunomodulatory PEG hydrogels.
Others have incorporated poly-L-lysine (PLL) onto surfaces to promote dendritic cell attachment [39] , and it is well known that positively charged groups on PLL result in the rapid binding of serum proteins to material surfaces, enabling cell interactions [40, 41] . Additionally, serum-coated surfaces (e.g., PLL-coated materials) have been used to limit the adjuvant effect [39, 42] , and are therefore a suitable platform for immunomodulation. BMDCs were seeded upon hydrogels functionalized with PLL and TGF-b1 and/or IL-10 and then stimulated. For PLL-hydrogels, an immunosuppressive effect was observed, as DC IL-12 production and surface marker expression on control and immunomodulatory hydrogels were decreased relative to controls. Further, T cell studies confirmed that PLL-hydrogels functionalized with immunomodulatory factors significantly reduced dendritic cell maturation. Ultimately, these findings indicated that decreased cellematerial interactions were a likely reason for limited signaling on unmodified immunomodulatory gels. Further, the immunosuppressive activity of PLL/immunomodulatory hydrogels towards BMDCs from NOD mice provides evidence that this sort of surface has the potential to interact favorably with DCs from type I diabetes.
Conclusion
We report a strategy for the introduction of immunosuppressive proteins, TGF-b1 and IL-10, into PEG hydrogels in a manner that preserves bioactivity towards iDCs. The immunomodulatory hydrogels reported herein reduced dendritic cell activation and possessed bioactivity that approached that of the soluble immunosuppressive proteins when cultured in the presence of the immortalized JAWSII DC cell line or primary BMDCs isolated from NOD mice. This technology suggests strategies for cell delivery applications, such as a coating of cell-laden biomaterials for the treatment of Type I diabetes, where it is desirable to limit the maturation of local dendritic cells and subsequently ameliorate the adaptive immune response.
